人类呼吸系统综合性病毒的瘤活动
D Dahrizal1, Ibrahim M Aziz2, Gani Asa Dudin1
1Politeknik Kesehatan Kemenkes Bengkulu, Indonesia.
Experimental oncology
|October 13, 2024
概括
瘤病毒 (OVs),像人类呼吸道同胞病毒 (RSV),通过向瘤和刺激免疫反应,在癌症治疗中表现有前途. RSV在各种癌细胞中表现出解性活性,这表明它在个性化癌症治疗中的潜力.
科学领域:
- 瘤治疗性病毒疗法
- 癌症免疫学 癌症免疫学
- 病毒学 病毒学
背景情况:
- 瘤病毒 (OV) 是用于癌症治疗的工程病毒.
- OVs提供瘤特定杀伤和免疫共同刺激.
- 人类呼吸道同胞性病毒 (RSV) 是一种RNA病毒,具有被证明的瘤性活性.
研究的目的:
- 讨论RSV的瘤治疗活性.
- 探索RSV在癌症治疗中的潜力.
- 突出RSV对癌细胞的作用机制.
主要方法:
- 对RSV的瘤解毒活性进行临床前研究的审查.
- 对参与RSV诱导的癌细胞死亡 (亡,自) 的分子途径的分析.
- 检查RSV与瘤微环境中的免疫反应的相互作用.
主要成果:
- RSV通过亡诱导癌细胞死亡,与NF-κB和STAT-1信号缺陷有关.
- 在宫癌细胞中,RSV通过ROS-BAX和TNF-α通路触发了自和亡.
- 在前列腺癌,肝细胞癌和皮肤癌的临床前模型中,RSV已经显示出有效性.
结论:
- 在各种癌症类型中,RSV表现出显著的瘤治疗潜力.
- RSV的机制包括亡和自诱导.
- 涉及RSV的组合疗法可能会改善传统治疗反应有限的患者的治疗结果.
更多相关视频
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
7.9K
09:14An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
10.8K
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.0K
Viral Recombination
23.3K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
23.3K
Acute Respiratory Failure-II
177
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
177
Acute Respiratory Failure-I
176
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
176
Acute Respiratory Failure-V
124
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
124
Acute Respiratory Failure-III
161
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
161
